Forigerimod

Drug Profile

Forigerimod

Alternative Names: CEP-33457; IPP-201101; Lupuzor; peptide P140; Rigerimod; SyB 1001

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator CNRS
  • Developer Cephalon; ImmuPharma
  • Class Oligopeptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Systemic lupus erythematosus
  • New Molecular Entity Yes
  • Available For Licensing Yes - Systemic lupus erythematosus

Highest Development Phases

  • Phase III Systemic lupus erythematosus

Most Recent Events

  • 22 Dec 2016 ImmuPharma completes enrolment in the phase III LUPUZOR trial for Systemic lupus erythematosus in USA, Germany, France, Italy, Czech Republic, Hungary, Poland, Puerto Rico, Mauritius and Italy
  • 14 Sep 2016 ImmuPharma initiates enrolment in the phase III LUPUZOR trial for Systemic lupus erythematosus in Czech Republic, France, Germany, Hungary and Poland (SC) (NCT02504645)
  • 07 Dec 2015 ImmuPharma initiates the phase III LUPUZOR trial for Systemic lupus erythematosus in USA (SC) (NCT02504645)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top